2
|
Creed SJ, Le CP, Hassan M, Pon CK, Albold S, Chan KT, Berginski ME, Huang Z, Bear JE, Lane JR, Halls ML, Ferrari D, Nowell CJ, Sloan EK. β2-adrenoceptor signaling regulates invadopodia formation to enhance tumor cell invasion. Breast Cancer Res 2015; 17:145. [PMID: 26607426 PMCID: PMC4660629 DOI: 10.1186/s13058-015-0655-3] [Citation(s) in RCA: 56] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2015] [Accepted: 11/09/2015] [Indexed: 01/11/2023] Open
Abstract
Introduction For efficient metastatic dissemination, tumor cells form invadopodia to degrade and move through three-dimensional extracellular matrix. However, little is known about the conditions that favor invadopodia formation. Here, we investigated the effect of β-adrenoceptor signaling - which allows cells to respond to stress neurotransmitters - on the formation of invadopodia and examined the effect on tumor cell invasion. Methods To characterize the molecular and cellular mechanisms of β-adrenergic signaling on the invasive properties of breast cancer cells, we used functional cellular assays to quantify invadopodia formation and to evaluate cell invasion in two-dimensional and three-dimensional environments. The functional significance of β-adrenergic regulation of invadopodia was investigated in an orthotopic mouse model of spontaneous breast cancer metastasis. Results β-adrenoceptor activation increased the frequency of invadopodia-positive tumor cells and the number of invadopodia per cell. The effects were selectively mediated by the β2-adrenoceptor subtype, which signaled through the canonical Src pathway to regulate invadopodia formation. Increased invadopodia occurred at the expense of focal adhesion formation, resulting in a switch to increased tumor cell invasion through three-dimensional extracellular matrix. β2-adrenoceptor signaling increased invasion of tumor cells from explanted primary tumors through surrounding extracellular matrix, suggesting a possible mechanism for the observed increased spontaneous tumor cell dissemination in vivo. Selective antagonism of β2-adrenoceptors blocked invadopodia formation, suggesting a pharmacological strategy to prevent tumor cell dissemination. Conclusion These findings provide insight into conditions that control tumor cell invasion by identifying signaling through β2-adrenoceptors as a regulator of invadopodia formation. These findings suggest novel pharmacological strategies for intervention, by using β-blockers to target β2-adrenoceptors to limit tumor cell dissemination and metastasis.
Collapse
Affiliation(s)
- Sarah J Creed
- Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
| | - Caroline P Le
- Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
| | - Mona Hassan
- Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
| | - Cindy K Pon
- Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
| | - Sabine Albold
- Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
| | - Keefe T Chan
- Department of Cell & Developmental Biology and Lineberger Comprehensive Cancer Center, School of Medicine, The University of North Carolina Chapel Hill, Chapel Hill, NC, 27599, USA. .,Current address: Peter MacCallum Cancer Centre, East Melbourne, VIC, 3002, Australia.
| | - Matthew E Berginski
- Department of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.
| | - Zhendong Huang
- Department of Mathematics and Statistics, The University of Melbourne, Parkville, VIC, 3010, Australia.
| | - James E Bear
- Department of Cell & Developmental Biology and Lineberger Comprehensive Cancer Center, School of Medicine, The University of North Carolina Chapel Hill, Chapel Hill, NC, 27599, USA.
| | - J Robert Lane
- Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
| | - Michelle L Halls
- Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
| | - Davide Ferrari
- Department of Mathematics and Statistics, The University of Melbourne, Parkville, VIC, 3010, Australia.
| | - Cameron J Nowell
- Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
| | - Erica K Sloan
- Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia. .,Cousins Center for PNI, UCLA Semel Institute, and Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, 90095, USA. .,Division of Cancer Surgery, Peter MacCallum Cancer Centre, East Melbourne, VIC, 3002, Australia.
| |
Collapse
|
3
|
Chan KT, Asokan SB, King SJ, Bo T, Dubose ES, Liu W, Berginski ME, Simon JM, Davis IJ, Gomez SM, Sharpless NE, Bear JE. LKB1 loss in melanoma disrupts directional migration toward extracellular matrix cues. ACTA ACUST UNITED AC 2015; 207:299-315. [PMID: 25349262 PMCID: PMC4210439 DOI: 10.1083/jcb.201404067] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The LKB1 kinase regulates directional migration in response to extracellular matrix gradients and may inhibit invasive motility by sensing inhibitory matrix cues. Somatic inactivation of the serine/threonine kinase gene STK11/LKB1/PAR-4 occurs in a variety of cancers, including ∼10% of melanoma. However, how the loss of LKB1 activity facilitates melanoma invasion and metastasis remains poorly understood. In LKB1-null cells derived from an autochthonous murine model of melanoma with activated Kras and Lkb1 loss and matched reconstituted controls, we have investigated the mechanism by which LKB1 loss increases melanoma invasive motility. Using a microfluidic gradient chamber system and time-lapse microscopy, in this paper, we uncover a new function for LKB1 as a directional migration sensor of gradients of extracellular matrix (haptotaxis) but not soluble growth factor cues (chemotaxis). Systematic perturbation of known LKB1 effectors demonstrated that this response does not require canonical adenosine monophosphate–activated protein kinase (AMPK) activity but instead requires the activity of the AMPK-related microtubule affinity-regulating kinase (MARK)/PAR-1 family kinases. Inhibition of the LKB1–MARK pathway facilitated invasive motility, suggesting that loss of the ability to sense inhibitory matrix cues may promote melanoma invasion.
Collapse
Affiliation(s)
- Keefe T Chan
- University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599
| | - Sreeja B Asokan
- University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599
| | - Samantha J King
- University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599
| | - Tao Bo
- University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599
| | - Evan S Dubose
- University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599
| | - Wenjin Liu
- University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599
| | - Matthew E Berginski
- University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599
| | - Jeremy M Simon
- University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599
| | - Ian J Davis
- University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599
| | - Shawn M Gomez
- University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599
| | - Norman E Sharpless
- University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599
| | - James E Bear
- University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599 University of North Carolina Lineberger Comprehensive Cancer Center, Department of Cell Biology and Physiology, Department of Genetics, Department of Biomedical Engineering, Carolina Center for Genome Science, Department of Pediatrics, and Howard Hughes Medical Institute, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599
| |
Collapse
|